BioSpace News Archive

Universal Health Services, Inc. announced that its reported net income attributable to UHS was $219.6 million, or $2.31 per diluted share, during the fourth quarter of 2017 as compared to $174.2 million, or $1.78 per diluted share, during the comparable quarter of 2016.

Concert Pharmaceuticals, Inc. announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet need.

Zymeworks Inc announced the addition of new clinical sites in Canada and the United States for its ongoing adaptive Phase 1 study of the company’s lead clinical candidate, ZW2.

C3J Therapeutics and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired function, announced an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.

Therap customers across Minnesota faced a seamless transition this month as a new mandate came into effect requiring daily service line items when submitting claims to the Department of Human Service’s MN-ITS billing system for Minnesota Health Care Programs (MHCP).

The Mission LISA Foundation is pleased to announce its new Advisory Board, a group of expert stakeholders engaged in combatting the national opioid crisis through research, pain and addiction treatment, industry, and advocacy.

Driven by its responsibility to protect and promote public health, the U.S. Food and Drug Administration (FDA) ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products.

Mylan N.V. and Revance Therapeutics, Inc. announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX® (onabotulinumtoxinA).

Allergan, Inc. announced that it was notified by the U.S. Food and Drug Administration (FDA) that the review of the New Drug Application (NDA) for ulipristal acetate will be extended.

Compassion & Choices Hawai’i applauds the Hawai’i House Health & Human Services (HHS) and Judiciary (JUD) Committees for their overwhelming 4 to 1 vote (HHS) and 7 to 1 vote (JUD) today to approve medical aid-in-dying legislation,"Our Care, Our Choice Act,” HB2739, for full House consideration following a joint public hearing on the bill on Monday.